On the public citation graph
Prevention of Chemotherapy-Induced Neutropenia with Pegfilgrastim: Pharmacokinetics and Patient Outcomes
0 signed · 135 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/(sici)1096-8652(199702)54:2<124::aid-ajh5>3.0.co;2-zopenalex-snapshot
Pharmacokinetics of intravenous recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children receiving myelosuppressive cancer chemotherapy: Clearance increases in relation to absolute neutrophil count with repeated dosing
inferredcites →https://doi.org/10.1002/9783527609628.ch15openalex-snapshot
Integration of Pharmacokinetics and Pharmacodynamics into the Drug Development of Pegfilgrastim, a Pegylated Protein
inferredcites →https://doi.org/10.1002/ajh.21805openalex-snapshot
Biosimilar epoetins and other “follow‐on” biologics: Update on the European experiences
inferredcites →https://doi.org/10.1002/biot.200900218openalex-snapshot
PEGylation of therapeutic proteins
inferredcites →https://doi.org/10.1002/jcp.1041240222openalex-snapshot
Binding of 125I‐labeled granulocyte colony‐stimulating factor to normal murine hemopoietic cells
inferredcites →https://doi.org/10.1002/jps.20024openalex-snapshot
Polyethylene Glycol Modification of Filgrastim Results in Decreased Renal Clearance of the Protein in Rats
inferredcites →https://doi.org/10.1007/bf01476870openalex-snapshot
Role of the kidney in hormone metabolism and its implications in clinical medicine
inferredcites →https://doi.org/10.1007/s00280-010-1281-5openalex-snapshot
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial
inferredcites →https://doi.org/10.1007/s00520-006-0201-zopenalex-snapshot
Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma
inferredcites →https://doi.org/10.1007/s10238-009-0072-yopenalex-snapshot
Chemotherapy-induced anemia in breast cancer patients treated with pegfilgrastim-supported dose-dense regimens
inferredcites →https://doi.org/10.1016/j.clinthera.2009.05.019openalex-snapshot
Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study
inferredcites →https://doi.org/10.1016/j.critrevonc.2006.12.007openalex-snapshot
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial
inferredcites →https://doi.org/10.1016/j.critrevonc.2009.06.004openalex-snapshot
Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy
inferredcites →https://doi.org/10.1016/j.ejca.2006.05.002openalex-snapshot
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
inferredcites →https://doi.org/10.1016/j.ejca.2008.11.021openalex-snapshot
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis
inferredcites →https://doi.org/10.1016/j.exphem.2003.09.007openalex-snapshot
Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells
inferredcites →https://doi.org/10.1016/s0169-409x(03)00108-xopenalex-snapshot
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates
inferredcites →https://doi.org/10.1016/s1548-5315(11)70402-8openalex-snapshot
Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegf lgrastim clinical trials: a retrospective analysis
inferredcites →https://doi.org/10.1023/a:1011534529622openalex-snapshot
Population Pharmacokinetic–Pharmacodynamic Modeling of Filgrastim (r-metHuG-CSF) in Healthy Volunteers
inferredcites →https://doi.org/10.1038/bjc.1988.163openalex-snapshot
In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients
inferredcites →https://doi.org/10.1038/ki.1979.128openalex-snapshot
Renal filtration, transport, and metabolism of low-molecular-weight proteins: A review
inferredcites →https://doi.org/10.1038/sj.bjc.6604862openalex-snapshot
A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer
inferredcites →https://doi.org/10.1038/sj.bmt.1703902openalex-snapshot
Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF
inferredcites →https://doi.org/10.1038/sj.thj.6200023openalex-snapshot
Polymorphonuclear leukocytes released from the bone marrow by granulocyte colony-stimulating factor: intravascular behavior
inferredcites →https://doi.org/10.1056/nejm199107183250305openalex-snapshot
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1067/mcp.2001.115455openalex-snapshot
Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: A conference report
inferredcites →https://doi.org/10.1080/1042819031000063462openalex-snapshot
Fixed-dose Pegfilgrastim is Safe and Allows Neutrophil Recovery in Patients with Non-Hodgkin's Lymphoma
inferredcites →https://doi.org/10.1080/1042819031000103953openalex-snapshot
Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma
inferredcites →https://doi.org/10.1084/jem.165.4.941openalex-snapshot
Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates.
inferredcites →https://doi.org/10.1093/annonc/mdf130openalex-snapshot
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: a multicenterdose-finding study in women with breast cancer
inferredcites →https://doi.org/10.1093/annonc/mdg019openalex-snapshot
A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
inferredcites →https://doi.org/10.1093/annonc/mdm438openalex-snapshot
Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
inferredcites →https://doi.org/10.1093/jac/43.suppl_3.21openalex-snapshot
In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis
inferredcites →https://doi.org/10.1093/jnci/84.15.1201openalex-snapshot
Severed Myelosuppression Resulting From Concurrent Administration of Granulocyte Colony-Stimulating Factor and Cytotoxic Chemotherapy
inferredcites →https://doi.org/10.1097/00001813-200304000-00002openalex-snapshot
Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients
inferredcites →https://doi.org/10.1097/jto.0b013e318186fb0dopenalex-snapshot
Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every 2 Weeks With Pegfilgrastim and Darbepoetin Alfa With and Without the Chemoprotector BNP7787 in Patients With Advanced Non-small Cell Lung Cancer (CALGB 30303)
inferredcites →https://doi.org/10.1097/jto.0b013e3181a52964openalex-snapshot
XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy
inferredcites →https://doi.org/10.1111/j.1524-4733.2007.00242.xopenalex-snapshot
Economic Analysis of Prophylactic Pegfilgrastim in Adult Cancer Patients Receiving Chemotherapy
inferredcites →https://doi.org/10.1126/science.232.4746.61openalex-snapshot
Recombinant Human Granulocyte Colony-Stimulating Factor: Effects on Normal and Leukemic Myeloid Cells
inferredcites →https://doi.org/10.1128/aac.43.1.21openalex-snapshot
Close Association between Clearance of Recombinant Human Granulocyte Colony-Stimulating Factor (G-CSF) and G-CSF Receptor on Neutrophils in Cancer Patients
inferredcites →https://doi.org/10.1128/aac.45.7.1947-1951.2001openalex-snapshot
Effects of Renal Function on Pharmacokinetics of Recombinant Human Granulocyte Colony-Stimulating Factor in Lung Cancer Patients
inferredcites →https://doi.org/10.1146/annurev.bi.58.070189.000401openalex-snapshot
HEMOPOIETIC CELL GROWTH FACTORS AND THEIR RECEPTORS
inferredcites →https://doi.org/10.1152/ajpendo.1995.269.1.e1openalex-snapshot
Receptor-mediated clearance of G-CSF derivative nartograstim in bone marrow of rats
inferredcites →https://doi.org/10.1159/000094890openalex-snapshot
Frequency of Febrile Neutropenia in Breast Cancer Patients Receiving Epirubicin and Docetaxel/Paclitaxel with Colony-Stimulating Growth Factors: A Comparison of Filgrastim or Lenograstim with Pegfilgrastim
inferredcites →https://doi.org/10.1159/000164588openalex-snapshot
Biological Effects of Pegfilgrastim on Circulating Neutrophils in Breast Cancer Patients Undergoing Dose-Dense Chemotherapy
inferredcites →https://doi.org/10.1159/000229504openalex-snapshot
Pegfilgrastim Administered on the Same Day with Dose-Dense Adjuvant Chemotherapy for Breast Cancer Is Associated with a Higher Incidence of Febrile Neutropenia as Compared to Conventional Growth Factor Support: Matched Case-Control Study of the Hellenic Cooperative Oncology Group
inferredcites →https://doi.org/10.1177/0091270008320318openalex-snapshot
Pharmacokinetics and Pharmacodynamics of Pegfilgrastim in Subjects With Various Degrees of Renal Function
inferredcites →https://doi.org/10.1177/0091270010376966openalex-snapshot
Population Modeling of Filgrastim PK‐PD in Healthy Adults Following Intravenous and Subcutaneous Administrations
inferredcites →https://doi.org/10.1182/blood-2008-07-162842openalex-snapshot
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG
inferredcites →https://doi.org/10.1182/blood.v114.22.4561.4561openalex-snapshot
Reported Bone Pain in Cancer Patients Receiving Chemotherapy in Pegfilgrastim Clinical Trials: A Retrospective Analysis.
inferredcites →https://doi.org/10.1182/blood.v68.1.162.162openalex-snapshot
Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors
inferredcites →https://doi.org/10.1182/blood.v72.6.2074.2074openalex-snapshot
Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients
inferredcites →https://doi.org/10.1182/blood.v74.4.1303.1303openalex-snapshot
Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor
inferredcites →https://doi.org/10.1182/blood.v77.10.2154.2154openalex-snapshot
Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo
inferredcites →https://doi.org/10.1182/blood.v78.11.2791.2791openalex-snapshot
Granulocyte colony-stimulating factor and its receptor
inferredcites →https://doi.org/10.1182/blood.v79.11.2849.2849openalex-snapshot
Pharmacokinetics of subcutaneous recombinant human granulocyte colony- stimulating factor in children
inferredcites →https://doi.org/10.1182/blood.v88.6.1907.bloodjournal8861907openalex-snapshot
Filgrastim (r-metHuG-CSF): the first 10 years
inferredcites →https://doi.org/10.1185/030079907x219599openalex-snapshot
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials
inferredcites →https://doi.org/10.1186/1471-2407-8-195openalex-snapshot
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial
inferredcites →https://doi.org/10.1186/1472-6955-2-2openalex-snapshot
The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study
inferredcites →https://doi.org/10.1200/jco.20.3.727openalex-snapshot
Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2000.18.13.2522openalex-snapshot
Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving Chemotherapy
inferredcites →https://doi.org/10.1200/jco.2002.02.140openalex-snapshot
Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs
inferredcites →https://doi.org/10.1200/jco.2003.03.040openalex-snapshot
Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma
inferredcites →https://doi.org/10.1200/jco.2003.05.002openalex-snapshot
Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices
inferredcites →https://doi.org/10.1200/jco.2005.02.8621openalex-snapshot
Efficacy of Pegfilgrastim and Darbepoetin Alfa As Hematopoietic Support for Dose-Dense Every-2-Week Adjuvant Breast Cancer Chemotherapy
inferredcites →https://doi.org/10.1200/jco.2005.09.102openalex-snapshot
First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study
inferredcites →https://doi.org/10.1200/jco.2006.05.7174openalex-snapshot
Myeloid Toxicity in Breast Cancer Patients Receiving Adjuvant Chemotherapy With Pegfilgrastim Support
inferredcites →https://doi.org/10.1200/jco.2006.06.4451openalex-snapshot
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
inferredcites →https://doi.org/10.1200/jco.2006.08.8823openalex-snapshot
Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review
inferredcites →https://doi.org/10.1200/jco.2009.24.8872openalex-snapshot
Phase II, Randomized, Open-Label Study of Pegfilgrastim-Supported VDC/IE Chemotherapy in Pediatric Sarcoma Patients
inferredcites →https://doi.org/10.1200/jco.2009.25.8723openalex-snapshot
Acute Myeloid Leukemia or Myelodysplastic Syndrome in Randomized Controlled Clinical Trials of Cancer Chemotherapy With Granulocyte Colony-Stimulating Factor: A Systematic Review
inferredcites →https://doi.org/10.1200/jop.091094openalex-snapshot
Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non–Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies
inferredcites →https://doi.org/10.1517/14712598.5.12.1635openalex-snapshot
Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action
inferredcites →https://doi.org/10.1517/14712598.8.7.993openalex-snapshot
Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor–expanding uses in cancer chemotherapy
inferredcites →https://doi.org/10.1592/phco.27.10.1387openalex-snapshot
Serum Pegfilgrastim Concentrations During Recovery of Absolute Neutrophil Count in Patients with Cancer Receiving Pegfilgrastim After Chemotherapy
inferredcites →https://doi.org/10.1615/critrevtherdrugcarriersyst.v25.i5.10openalex-snapshot
PEGylation: An Approach for Drug Delivery. A Review
inferredcites →https://doi.org/10.1634/theoncologist.12-12-1416openalex-snapshot
Elderly Cancer Patients Receiving Chemotherapy Benefit from First-Cycle Pegfilgrastim
inferredcites →https://doi.org/10.1634/theoncologist.12-4-484openalex-snapshot
Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use
inferredcites →https://doi.org/10.2165/00003495-200262001-00005openalex-snapshot
Filgrastim in Patients with Neutropenia
inferredcites →https://doi.org/10.2165/00063030-200822050-00004openalex-snapshot
The Impact of PEGylation on Biological Therapies
inferredcites →https://doi.org/10.2165/11318090-000000000-00000openalex-snapshot
Population Pharmacokinetic Modelling of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations
inferredcites →https://doi.org/10.2165/11586040-000000000-00000openalex-snapshot
Pharmacokinetics and Pharmacodynamics of Pegfilgrastim
inferredcites →https://doi.org/10.2174/1381612043452613openalex-snapshot
The Design and Development of Pegfilgrastim (PEG-rmetHuG-CSF, Neulasta®)
inferredcites →https://doi.org/10.3109/03602539608994020openalex-snapshot
Pharmacokinetics and Pharmacodynamics of a Recombinant Human Granulocyte Colony-Stimulating Factor
inferredcites →https://doi.org/10.3322/canjclin.46.3.165openalex-snapshot
Hematopoietic growth factors
inferredcites →https://doi.org/10.3816/cbc.2003.n.003openalex-snapshot
Bone Pain Associated with Once-Per-Cycle Pegfilgrastim Is Similar to Daily Filgrastim in Patients with Breast Cancer
inferredcites →https://doi.org/10.3816/ccc.2010.n.013openalex-snapshot
A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy
inferredcites →https://doi.org/10.6004/jnccn.2008.0012openalex-snapshot
Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology Practice
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4861052openalex-extracted
An Open-Label, Randomized Phase III Study of Telpegfilgrastim in Preventing Chemotherapy-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1002/cpdd.819openalex-snapshot
Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony‐Stimulating Factor in Healthy Chinese Subjects: An Open‐Label, Randomized, Parallel‐Design Bioavailability Study
inferred← citeshttps://doi.org/10.1002/iid3.1348openalex-snapshot
A multicenter, prospective, non‐interventional real‐world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer
inferred← citeshttps://doi.org/10.1007/s00280-021-04355-6openalex-snapshot
Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer
inferred← citeshttps://doi.org/10.1007/s00520-014-2457-zopenalex-snapshot
Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review
inferred← citeshttps://doi.org/10.1007/s40259-015-0127-4openalex-snapshot
Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor
inferred← citeshttps://doi.org/10.1016/j.biotechadv.2024.108467openalex-snapshot
Implications of glycosylation for the development of selected cytokines and their derivatives for medical use
inferred← citeshttps://doi.org/10.1016/j.breast.2021.02.014openalex-snapshot
Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2020.103193openalex-snapshot
Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review
inferred← citeshttps://doi.org/10.1016/j.exphem.2016.09.003openalex-snapshot
Pharmacological inhibition of AKT activity in human CD34+ cells enhances their ability to engraft immunodeficient mice
inferred← citeshttps://doi.org/10.1016/j.jconrel.2014.05.001openalex-snapshot
Polymer therapeutics: Top 10 selling pharmaceuticals — What next?
inferred← citeshttps://doi.org/10.1016/j.psym.2016.08.007openalex-snapshot
Use of Granulocyte Colony-Stimulating Factor in a Neutropenic HIV-Infected Patient on Clozapine
inferred← citeshttps://doi.org/10.1021/la403607mopenalex-snapshot
Low Temperature Thermal Dependent Filgrastim Adsorption Behavior Detected with ToF-SIMS
inferred← citeshttps://doi.org/10.1039/c6py00080kopenalex-snapshot
Enhancing the conjugation yield of brush polymer–protein conjugates by increasing the linker length at the polymer end-group
inferred← citeshttps://doi.org/10.1080/0284186x.2019.1670353openalex-snapshot
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer
inferred← citeshttps://doi.org/10.1080/14656566.2021.1873950openalex-snapshot
Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars
inferred← citeshttps://doi.org/10.1136/bmjspcare-2019-001862openalex-snapshot
The prophylactic effects of long-acting granulocyte colony-stimulating factor for febrile neutropenia in newly diagnosed patients with epithelial ovarian cancer: a randomised controlled study
inferred← citeshttps://doi.org/10.1136/bmjspcare-2021-003082openalex-snapshot
Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment
inferred← citeshttps://doi.org/10.1136/jclinpath-2020-207114openalex-snapshot
Choosing wisely during the COVID-19 pandemic: optimising outpatient cancer care while conserving resources with a new algorithm to report automated ANC results
inferred← citeshttps://doi.org/10.1158/2767-9764.crc-25-0770openalex-snapshot
Chemotherapy-Induced Neutropenia in Palestinian Patients with Solid Malignancies: Patient Characteristics, Severity Risk Factors, and Management Patterns
inferred← citeshttps://doi.org/10.1159/000351114openalex-snapshot
Efficacy of Oral Cytarabine Ocfosfate and Etoposide in the Treatment of Elderly Patients with Higher-Risk Myelodysplastic Syndromes Compared to That in Elderly Acute Myeloid Leukemia Patients
inferred← citeshttps://doi.org/10.1159/000357468openalex-snapshot
Bendamustine as Monotherapy and in Combination Regimens for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma: A Retrospective Analysis
inferred← citeshttps://doi.org/10.1159/000362498openalex-snapshot
First-Line Combination Chemotherapy with Cisplatin, Etoposide and Ifosfamide for the Treatment of Disseminated Germ Cell Cancer: Re-Evaluation in the Granulocyte Colony-Stimulating Factor Era
inferred← citeshttps://doi.org/10.1159/000479067openalex-snapshot
Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis
inferred← citeshttps://doi.org/10.1177/1078155215625459openalex-snapshot
Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review
inferred← citeshttps://doi.org/10.1177/1078155220945771openalex-snapshot
Retrospective study evaluating the safety of administering pegfilgrastim on the final day of 5-fluorouracil continuous intravenous infusion
inferred← citeshttps://doi.org/10.1186/s12885-024-13296-1openalex-snapshot
Effects of long-acting versus short-acting granulocyte colony stimulating factor after radiotherapy in gynecologic malignancies: a prospective observational cohort study
inferred← citeshttps://doi.org/10.1186/s12885-025-13736-6openalex-snapshot
Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study
inferred← citeshttps://doi.org/10.1208/s12248-019-0349-3openalex-snapshot
Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies
inferred← citeshttps://doi.org/10.1371/journal.pone.0288642openalex-snapshot
Prescription patterns of granulocyte colony–stimulating factors in patients with breast cancer: A real-world study
inferred← citeshttps://doi.org/10.21037/atm.2019.10.61openalex-snapshot
A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available
inferred← citeshttps://doi.org/10.2147/cmar.s301027openalex-snapshot
Optimizing Dose-Adjusted EPOCH Chemotherapy with Long-Acting Granulocyte Colony-Stimulating Factor During the COVID-19 Epidemic
inferred← citeshttps://doi.org/10.2147/jbm.s186786openalex-snapshot
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
inferred← citeshttps://doi.org/10.2165/11586040-000000000-00000openalex-snapshot
Pharmacokinetics and Pharmacodynamics of Pegfilgrastim
inferred← citeshttps://doi.org/10.26616/nioshheta201300193205openalex-snapshot
Evaluation of chemotherapy drug exposure in an outpatient infusion center.
inferred← citeshttps://doi.org/10.26689/par.v4i6.1680openalex-snapshot
PEG-rhG-CSF Use Reduces Glucose Level Significantly in Cancer Patients Receiving Chemotherapy
inferred← citeshttps://doi.org/10.29011/2577-1418.000133openalex-snapshot
Biosimilar Filgrastim (Nivestim®) in the Treatment and Prevention of Chemotherapy-Induced Neutropenia: Results of the NEXT Observational Study
inferred← citeshttps://doi.org/10.3389/fncel.2014.00464openalex-snapshot
Gene expression changes in spinal motoneurons of the SOD1G93A transgenic model for ALS after treatment with G-CSF
inferred← citeshttps://doi.org/10.3389/fonc.2022.1026377openalex-snapshot
New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy
inferred← citeshttps://doi.org/10.3390/biology10101069openalex-snapshot
Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis
inferred← citeshttps://doi.org/10.5451/unibas-006359388openalex-snapshot
Neutropenia in cancer patients, risk prediction models of neutropenia, and supportive measures
inferred← citeshttps://doi.org/10.5505/tjo.2019.2087openalex-snapshot
Single Center Experiences with Pegfilgrastim as Secondary Prophylaxis
inferred← citeshttps://doi.org/10.7499/j.issn.1008-8830.2005048openalex-snapshot
[Pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a prospective control trial].
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.